12-12717870-C-T
Variant summary
Our verdict is Uncertain significance. The variant received 0 ACMG points: 0P and 0B.
The NM_004064.5(CDKN1B):c.31C>T(p.Pro11Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000415 in 1,613,724 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P11R) has been classified as Uncertain significance.
Frequency
Consequence
NM_004064.5 missense
Scores
Clinical Significance
Conservation
Publications
- multiple endocrine neoplasia type 4Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet, ClinGen
- multiple endocrine neoplasiaInheritance: AD Classification: STRONG Submitted by: G2P
- hereditary nonpolyposis colon cancerInheritance: AR Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152204Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000400 AC: 10AN: 250052 AF XY: 0.0000443 show subpopulations
GnomAD4 exome AF: 0.0000424 AC: 62AN: 1461520Hom.: 0 Cov.: 50 AF XY: 0.0000440 AC XY: 32AN XY: 727076 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152204Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74358 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Multiple endocrine neoplasia type 4 Uncertain:3
- -
This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 11 of the CDKN1B protein (p.Pro11Ser). This variant is present in population databases (rs779193240, gnomAD 0.007%). This missense change has been observed in individual(s) with prostate cancer (PMID: 17372254). ClinVar contains an entry for this variant (Variation ID: 404268). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
not provided Uncertain:2
The CDKN1B c.31C>T (p.Pro11Ser) variant has been reported in the published literature in an individual affected with prostate cancer (PMID: 17372254 (2007)). The frequency of this variant in the general population, 0.000071 (8/113000 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with prostate cancer (Cybulski et al., 2007); This variant is associated with the following publications: (PMID: 17372254) -
Ovarian cancer Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at